A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV/ Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (CYPRESS - 2)

June 22, 2018
Principal Investigator: Igor I Rybkin, MD
lung cancer, lung, cancer, CYPRESS 2, ARMO
Accepting Participants